Experiences with
Rituximab2,596 public posts
The Leukemia & Lymphoma Society’s National Patient Registry COVID-19 vaccination antibody results - published today (Greenberg et al)
Data collected March 12 to May 5, 2021
-
COVID-19 Vaccine Antibody Response among CLL Patients by Type of Treatment
Treatment within the past 2 years Percent of patients seronegative
None 17
Obinutuzumab 90
Rituximab, acalabrutinib 85
Rituximab, ibrutinib 77
Multidrug therapy w or w/o
Want to take advantage of all our features? Just log in!
or
THE 2021 EUROPEAN GROUP ON GRAVES' ORBITOPATHY (EUGOGO) CLINICAL PRACTICE GUIDELINES FOR THE MEDICAL MANAGEMENT OF GRAVES' ORBITOPATHY
active GO include: a) a second course of iv methylprednisolone (7.5 g) subsequent to careful ophthalmic and biochemical evaluation, b) oral prednisone/prednisolone combined with either cyclosporine or azathioprine; c) orbital radiotherapy combined with oral or iv glucocorticoids, d) teprotumumab; e) rituximab
STELLAR Trial in the UK for Richter's
This is a combination of chemotherapy drugs and a targeted drug called rituximab. This treatment can help and cure some people but sometimes the lymphoma comes back, so researchers are looking for ways to improve treatment.
Important SARS-CoV-2 and Covid-19 information for Chronic Lymphocytic Leukaemia/CLL patients
In addition, they may experience:
• Treatment-related immunodeficiency (such as that resulting from anti-CD20 monoclonal antibody treatment such as Rituximab (Mabthera/Rituxan), Obinutuzumab (Gazyva) or ofatumumab (Arzerra)
In a recent study, ‘individual risk factors associated with a poor prognosis